TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02116530
Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral or IV
Study: NCT02300376
Drug: Dosage of Calcium edetate de sodium
Normalized name: edetate calcium
DrugBank: Edetate sodium (DB13404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
Study: NCT05139966
Drug: Mouthwash Product
Normalized name: Mouthwash Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
Study: NCT01225107
Drug: Inert Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert substance, 3 times per day in capsule form
Study: NCT03056326
Drug: Placebo (Part 1 - SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of placebo matching CHF6333 at each period
Study: NCT03056326
Drug: Placebo (Part 2 - MAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily multiple doses of placebo matching CHF6333 for 14 days
Study: NCT01776047
Drug: Exforge®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01776047
Drug: G-0081
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04646278
Drug: Hyperemic stimuli
Normalized name: STIMULEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperemic simuli of coronary flow by adenosine or nicorandil injection
Study: NCT00647608
Drug: Inderal® LA Capsules 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160mg, single dose fed
Study: NCT01114113
Drug: pancelipase/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule.
Study: NCT01231347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously on days 1 and 15 of a 28 day cycle
Study: NCT03849443
Drug: Vitamin C 250 MG Oral Tablet
Normalized name: vitamin C 250 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral method of placebo
Study: NCT00606684
Drug: GW642444 3mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00606684
Drug: GW642444 12.5mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW642444 12.5mcg
Study: NCT00606684
Drug: GW642444 25mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW642444 25mcg
Study: NCT00606684
Drug: GW642444 50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW642444 50mcg
Study: NCT02763579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
Study: NCT00006721
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00006721
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03760133
Drug: Duolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
Study: NCT00406094
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00135733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02647437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00273910
Drug: gp100:209-217 (210M)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04480099
Drug: CHOP+X
Approvals — FDA: no, EMA: no, PMDA: no
Description: X: X(i.e. targeted drug) will decided by NGS results as following. Decitabine 10mg/m2 ivgtt D-5 to-1 if with TP53 gene muation. Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation. Chidamide 20mg/day po D1,4,8,11 if with CREBBP/EP300 gene mutation. Lenalidomide 25mg/day po D1-10 if without gene mutation above. X will be added from the second cycle CHOP:Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
Study: NCT02671773
Drug: Inhaled corticosteroid dose/type
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01241773
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 75 mg capsules once daily for 7 days
Study: NCT01241773
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 75 mg capsules once daily for 14 days
Study: NCT00973271
Drug: 290 mg DCCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 290 mg diazoxide choline
Study: NCT00973271
Drug: 435 mg DCCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 435 mg diazoxide choline
Study: NCT00973271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
Study: NCT01882400
Drug: Bisphosphonate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
Study: NCT01998685
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00377728
Drug: GSK256066
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01410383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken daily
Study: NCT02579083
Drug: MB66
Normalized name: Metformin and Biguanide 66
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
Study: NCT02579083
Drug: Placebo Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
Study: NCT01764854
Drug: Placebo (in-patient)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, size and color matched to experimental drug administered in a CPU
Study: NCT01764854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, size and color matched to experimental drug
Study: NCT01087879
Drug: Desogestrel-Ethinyl Estradiol contraceptive pill
Normalized name: desogestrel / ethinyl estradiol Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
Study: NCT01087879
Drug: Etonogestrel-Ethinyl Estradiol vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
Study: NCT01087879
Drug: Norelgestromin-Ethinyl Estradiol contraceptive patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
Study: NCT01486706
Drug: Placebo drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: will titrate medications similar to the active drug group
Study: NCT00040859
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01464359
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours.
Study: NCT00647049
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8000mg/m2 i.v., max. 2 cycles
Study: NCT03273387
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
Study: NCT01580358
Drug: Shen-Mai San
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
Study: NCT02101203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02101203
Drug: 0.5 mgTestosterone + 10 mg Buspirone
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days).
Study: NCT01962831
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02001181
Drug: Placebo ointment (Vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (vehicle) twice daily (BID) for 4 weeks
Study: NCT00771316
Drug: MK0826 (ertapenem)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 1.0g IV infused over a 30 minute interval at hour 0
Study: NCT02027376
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04171284
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, Q3W, maximum treatment up to six cycles
Study: NCT01244815
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Study: NCT00806338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00945555
Drug: Antibacterial agent for the treatment of febrile neutropenia
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
Study: NCT02612129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04226547
Drug: Non-Vitamin K Oral Antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation or continuation of a NOAC drug
Study: NCT00704262
Drug: Calcipotriol plus hydrocortisone (LEO 80190)
Normalized name: hydrocortisone Rectal Cream [Recort Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application
Study: NCT03332771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT03332771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT01039974
Drug: GSK962040
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1
Study: NCT02345278
Drug: SUBLIVAC FIX Mite mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
Study: NCT04426201
Drug: CYT107
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study: NCT04426201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same number, volume and frequency of IM administration of saline
Study: NCT01043146
Drug: COR-1
Normalized name: Corticosteroid-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
Study: NCT01043146
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous 0.9 % NaCl
Study: NCT00478881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
Study: NCT00473473
Drug: Placebo homeopathic remedy
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical to treatment without active component
Study: NCT00894023
Drug: Intracoronary bolus wtih ClearWay™RX catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary bolus with Clearway catheter
Study: NCT01854203
Drug: Inductive chemotherapy + IMRT
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
Study: NCT01777347
Drug: 3% Saline
Normalized name: dextrose 2.5%-0.3% saline (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 4 mL nebulization of 3% saline with 20 minutes interval
Study: NCT00288171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule twice daily for one month
Study: NCT02611960
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral tablet
Study: NCT00555685
Drug: NaCl 7,5% (Hypertonic Saline Solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
Study: NCT00555685
Drug: NaCl 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
Study: NCT04204122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: -The placebo is artificial tear drops
Study: NCT00080275
Drug: Niacin Extended-Release and simvastatin Tablets
Normalized name: niacin / simvastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02818556
Drug: Belotero Balance
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01698320
Drug: Placebo MDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
Study: NCT00359970
Drug: Azithromycin 500 mg
Normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single 500 mg dose at the start of treatment
Study: NCT00359970
Drug: Azithromycin 1000 mg
Normalized name: azithromycin 1000 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single 1000 mg dose at the start of treatment
Study: NCT01189240
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00518518
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02005432
Drug: panfotocoagulation (PASCAL)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02005432
Drug: panfotocoagulation (PRP) single shoot (ETDRS)
Normalized name: Toxicodendron pubescens shoot extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03126370
Drug: TDF with a boosted protease inhibitor
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment
Study: NCT03126370
Drug: TAF with a boosted protease inhibitor
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment
Study: NCT03126370
Drug: TAF with a boosted protease inhibitor and LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment
Study: NCT01264211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
Study: NCT02495467
Drug: MED Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
Study: NCT01008397
Drug: AHIST NDC#58407-012-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet containing chlorpheniramine tannate 12mg.
Study: NCT02268955
Drug: IV Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
Study: NCT02416583
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01567735
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
Study: NCT00580970
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
Study: NCT02414451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules
Study: NCT04275219
Drug: The Placebo of Tongfu capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo of Tongfu capsules are made from dextrin, starch and so on.
Study: NCT03985384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1.5 ml, pen-injector for SC injection.
Study: NCT00943124
Drug: MK0524B (ER niacin (+) laropiprant (+) simvastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
Study: NCT00943124
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
Study: NCT02185755
Drug: Normal Medication Positive Control
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00730197
Drug: VoSpire® ER Tablets 8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg, single dose fed
Study: NCT00974766
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
Study: NCT00974766
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
Study: NCT02892123
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
Study: NCT00814658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo three times a day (tid).
Study: NCT03801733
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Simvastatin
Study: NCT03801733
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Rosuvastatin
Study: NCT03801733
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Pravastatin